0001591986-22-000015.txt : 20220428
0001591986-22-000015.hdr.sgml : 20220428
20220428161308
ACCESSION NUMBER: 0001591986-22-000015
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220426
FILED AS OF DATE: 20220428
DATE AS OF CHANGE: 20220428
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aquilo Capital, L.P.
CENTRAL INDEX KEY: 0001491371
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38266
FILM NUMBER: 22866686
BUSINESS ADDRESS:
STREET 1: ONE LETTERMAN DRIVE, SUITE D4900
STREET 2: BUILDING D, THE PRESIDIO
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94129
BUSINESS PHONE: (415) 635-0141
MAIL ADDRESS:
STREET 1: ONE LETTERMAN DRIVE, SUITE D4900
STREET 2: BUILDING D, THE PRESIDIO
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aquilo Capital Management, LLC
CENTRAL INDEX KEY: 0001591986
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38266
FILM NUMBER: 22866687
BUSINESS ADDRESS:
STREET 1: ONE LETTERMAN DRIVE
STREET 2: SUITE D4900, BUILDING D
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94129
BUSINESS PHONE: 415-635-0140
MAIL ADDRESS:
STREET 1: ONE LETTERMAN DRIVE
STREET 2: SUITE D4900, BUILDING D
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94129
FORMER NAME:
FORMER CONFORMED NAME: Aquilo Capital Managment, LLC
DATE OF NAME CHANGE: 20131114
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701108
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-242-1600
MAIL ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Spero Therapeutics, LLC
DATE OF NAME CHANGE: 20170316
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2022-04-26
0
0001701108
Spero Therapeutics, Inc.
SPRO
0001591986
Aquilo Capital Management, LLC
ONE LETTERMAN DRIVE
SUITE D4900, BUILDING D
SAN FRANCISCO
CA
94129
0
0
1
0
0001491371
Aquilo Capital, L.P.
ONE LETTERMAN DRIVE, SUITE D4900
BUILDING D, THE PRESIDIO
SAN FRANCISCO
CA
94129
0
0
1
0
Common Stock, $0.001 par value
2022-04-26
4
P
0
39727
5.235
A
5321231
I
See Footnotes
The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein.
Aquilo Capital, LP only owns 3,511,982 of the 5,321,231 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 39,727 shares in this transaction on 4/26/2022.
Aquilo Capital Management, LLC By: Marc Schneidman, its Managing Member, /s/ Marc Schneidman
2022-04-28
Aquilo Capital, L.P., By: Aquilo Capital Management, LLC, its General Partner By: Marc Schneidman, its Managing Member /s/ Marc Schneidman
2022-04-28